Multidrug-resistant tuberculosis in Denmark 1993-1995

Int J Tuberc Lung Dis. 1997 Aug;1(4):299-301.


Setting: All bacteriologically confirmed new cases of tuberculosis and treatment relapses in Denmark are examined for drug resistance. In the years 1993-1995, nine cases of multidrug-resistant tuberculosis (MDR-TB), all acquired outside Denmark, were identified among 1354 cases of tuberculosis.

Objective: To examine incidence, treatment and prognosis for patients with tuberculosis due to MDR Mycobacterium tuberculosis.

Design: Retrospective evaluation of routine data.

Results and conclusion: Multidrug resistance was present in less than one present of patients with tuberculosis. One patient died from tuberculosis without revision of treatment, and eight patients responded favourably to a regimen of pyrazinamide, streptomycin or amikacin, ofloxacin and cycloserine. In two patients, this regimen was supplemented with para-aminosalicylic acid and thiacetazone respectively. All patients needed prolonged hospitalization and had observed treatment. It is possible to cure such patients, but it is a lengthy and expensive process. It is expected that similar cases will be imported into the country and that they will occur within Denmark in the future.

MeSH terms

  • AIDS-Related Opportunistic Infections / economics
  • AIDS-Related Opportunistic Infections / epidemiology*
  • AIDS-Related Opportunistic Infections / prevention & control
  • Adult
  • Antitubercular Agents / adverse effects
  • Antitubercular Agents / economics
  • Antitubercular Agents / therapeutic use
  • Child, Preschool
  • Cost-Benefit Analysis
  • Cross-Sectional Studies
  • Denmark / epidemiology
  • Drug Therapy, Combination
  • Female
  • Humans
  • Incidence
  • Long-Term Care / economics
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Mycobacterium tuberculosis / drug effects
  • Retrospective Studies
  • Tuberculosis, Multidrug-Resistant / economics
  • Tuberculosis, Multidrug-Resistant / epidemiology*
  • Tuberculosis, Multidrug-Resistant / prevention & control


  • Antitubercular Agents